NeoGenomics, Inc. (NEO)Healthcare | Diagnostics & Research | Fort Myers, United States | NasdaqCM
16.89 USD
+0.69
(4.259%)
⇧
(Oct. 13, 2026, 2:18 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 1:37 a.m. EDT
The immediate outlook is mixed but leans cautiously positive due to a sharp technical rebound. The stock has recovered significantly from its lows, trading well above its 200-day moving average, which suggests institutional accumulation. However, the fundamental picture remains precarious: the company is losing money, with negative operating margins and a forward P/E that implies high expectations for future profitability that haven't materialized yet. The heavy put activity in the options chain acts as a warning sign, reflecting deep-seated fears of further deterioration or a failed turnaround attempt. While the recent price action shows resilience, the lack of consistent profitability and the defensive positioning by traders suggest this is more of a speculative recovery play than a confirmed trend reversal. Investors should watch for a break above the recent highs to confirm the uptrend, as the current setup looks like a volatile consolidation phase. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.039979 |
| AutoETS | 0.099215 |
| MSTL | 0.120362 |
| AutoARIMA | 0.168633 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 37% |
| H-stat | 2.68 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.678 |
| Excess Kurtosis | 0.42 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 57.064 |
| Revenue per Share | 5.942 |
| Market Cap | 2,199,276,800 |
| Forward P/E | 49.28 |
| Beta | 1.78 |
| Profit Margins | -6.77% |
| Website | https://www.neogenomics.com |
As of Oct. 10, 2026, 1:37 a.m. EDT: Speculators are heavily positioned for downside protection, with massive open interest in deep out-of-the-money puts (strikes 6.0 and 9.0) expiring in December 2026, suggesting a fear of a significant drop to near-half prices. Conversely, call activity is concentrated in the money and slightly out-of-the-money strikes (16.0 to 19.0) for near-term expiration, indicating a belief in a modest bounce or consolidation around current levels rather than a massive rally. The skew in volume and open interest strongly favors the put side for longer-dated contracts.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.7270789 |
| Address1 | 9,490 NeoGenomics Way |
| All Time High | 61.57 |
| All Time Low | 0.12 |
| Ask | 20.56 |
| Ask Size | 2 |
| Audit Risk | 5 |
| Average Analyst Rating | 1.7 - Buy |
| Average Daily Volume10 Day | 2,636,710 |
| Average Daily Volume3 Month | 2,386,651 |
| Average Volume | 2,386,651 |
| Average Volume10Days | 2,636,710 |
| Beta | 1.784 |
| Bid | 11.96 |
| Bid Size | 2 |
| Board Risk | 1 |
| Book Value | 6.142 |
| City | Fort Myers |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 16.89 |
| Current Ratio | 3.603 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 16.98 |
| Day Low | 15.9796 |
| Debt To Equity | 57.064 |
| Display Name | NeoGenomics |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,785,268,800 |
| Earnings Call Timestamp Start | 1,785,268,800 |
| Earnings Timestamp | 1,785,268,800 |
| Earnings Timestamp End | 1,793,131,200 |
| Earnings Timestamp Start | 1,793,131,200 |
| Ebitda | 24,325,000 |
| Ebitda Margins | 0.03174 |
| Enterprise To Ebitda | 98.012 |
| Enterprise To Revenue | 3.111 |
| Enterprise Value | 2,384,131,072 |
| Eps Current Year | 0.18545 |
| Eps Forward | 0.34273 |
| Eps Trailing Twelve Months | -0.39 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 239 690 4237 |
| Fifty Day Average | 17.471 |
| Fifty Day Average Change | -0.5810013 |
| Fifty Day Average Change Percent | -0.033255182 |
| Fifty Two Week Change Percent | 72.70789 |
| Fifty Two Week High | 20.15 |
| Fifty Two Week High Change | -3.2600002 |
| Fifty Two Week High Change Percent | -0.16178662 |
| Fifty Two Week Low | 7.07 |
| Fifty Two Week Low Change | 9.82 |
| Fifty Two Week Low Change Percent | 1.3889674 |
| Fifty Two Week Range | 7.07 - 20.15 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,079,447,400,000 |
| Float Shares | 116,965,325 |
| Forward Eps | 0.34273 |
| Forward P E | 49.280777 |
| Free Cashflow | 43,904,752 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 2,500 |
| Fullday Change | 0.6899986 |
| Fullday Change Percent | 4.2592506 |
| Fullday Price | 16.89 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.43917 |
| Gross Profits | 336,531,008 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.021140002 |
| Held Percent Institutions | 1.15181 |
| Implied Shares Outstanding | 130,211,780 |
| Industry | Diagnostics & Research |
| Industry Disp | Diagnostics & Research |
| Industry Key | diagnostics-research |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. The company was founded in 2001 and is headquartered in Fort Myers, Florida. |
| Long Name | NeoGenomics, Inc. |
| Market | us_market |
| Market Cap | 2,199,276,800 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_1335304 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -51,878,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,358,809,078 |
| Number Of Analyst Opinions | 10 |
| Open | 16.3 |
| Operating Cashflow | 22,049,000 |
| Operating Margins | -0.048449997 |
| Overall Risk | 3 |
| Payout Ratio | 0.0 |
| Peg Ratio | 2.09 |
| Phone | 239 768 0600 |
| Previous Close | 16.2 |
| Price Eps Current Year | 91.07576 |
| Price Hint | 2 |
| Price To Book | 2.7499185 |
| Price To Sales Trailing12 Months | 2.8700132 |
| Profit Margins | -0.0677 |
| Quick Ratio | 3.036 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.66667 |
| Region | US |
| Regular Market Change | 0.6899986 |
| Regular Market Change Percent | 4.2592506 |
| Regular Market Day High | 16.98 |
| Regular Market Day Low | 15.9796 |
| Regular Market Day Range | 15.9796 - 16.98 |
| Regular Market Open | 16.3 |
| Regular Market Previous Close | 16.2 |
| Regular Market Price | 16.89 |
| Regular Market Time | 1,791,915,505 |
| Regular Market Volume | 1,097,760 |
| Return On Assets | -0.018860001 |
| Return On Equity | -0.06327 |
| Revenue Growth | 0.112 |
| Revenue Per Share | 5.942 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 3 |
| Shares Outstanding | 130,211,780 |
| Shares Percent Shares Out | 0.1101 |
| Shares Short | 14,150,681 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 15,759,505 |
| Short Name | NeoGenomics, Inc. |
| Short Percent Of Float | 0.13 |
| Short Ratio | 6.99 |
| Source Interval | 15 |
| State | FL |
| Symbol | NEO |
| Target High Price | 35.0 |
| Target Low Price | 16.0 |
| Target Mean Price | 21.55 |
| Target Median Price | 20.0 |
| Total Cash | 145,539,008 |
| Total Cash Per Share | 1.133 |
| Total Debt | 448,368,000 |
| Total Revenue | 766,294,976 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.39 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 12.4676 |
| Two Hundred Day Average Change | 4.4223995 |
| Two Hundred Day Average Change Percent | 0.35471138 |
| Type Disp | Equity |
| Volume | 1,097,760 |
| Website | https://www.neogenomics.com |
| Zip | 33,912 |